Humacyte, Inc. (HUMA)
NASDAQ: HUMA · Real-Time Price · USD
0.848
+0.042 (5.16%)
At close: Apr 28, 2026, 4:00 PM EDT
0.850
+0.003 (0.29%)
After-hours: Apr 28, 2026, 6:00 PM EDT
Humacyte Employees
Humacyte had 184 employees as of December 31, 2025. The number of employees decreased by 36 or -16.36% compared to the previous year.
Employees
184
Change (1Y)
-36
Growth (1Y)
-16.36%
Revenue / Employee
$11,076
Profits / Employee
-$221,918
Market Cap
188.16M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 184 | -36 | -16.36% |
| Dec 31, 2024 | 220 | 35 | 18.92% |
| Dec 31, 2023 | 185 | 21 | 12.80% |
| Dec 31, 2022 | 164 | 18 | 12.33% |
| Dec 31, 2021 | 146 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 293 |
| Tonix Pharmaceuticals Holding | 142 |
| Cartesian Therapeutics | 75 |
| Precision BioSciences | 68 |
| Acumen Pharmaceuticals | 61 |
| Korro Bio | 58 |
| Corbus Pharmaceuticals Holdings | 36 |
| Unicycive Therapeutics | 22 |
HUMA News
- 10 hours ago - Humacyte Transcript: KOL event - Transcripts
- 1 day ago - Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026 - GlobeNewsWire
- 3 days ago - Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA - PRNewsWire
- 4 days ago - Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess® - GlobeNewsWire
- 6 days ago - Humacyte Appoints Jim Mercadante as Chief Commercial Officer - GlobeNewsWire
- 7 days ago - Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma Repair - GlobeNewsWire
- 19 days ago - Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PRNewsWire
- 4 weeks ago - Humacyte Earnings Call Transcript: Q4 2025 - Transcripts